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The pro form of neurotrophic growth factor (pro-NGF),
purified by chromatography from human Alzheimer’s
disease (AD)-affected brains (ADhbi-pro-NGF), has been
shown to induce apoptotic cell death in neuronal cell
cultures through its interaction with the p75 neurotro-
phin receptor (p75NTR). In the present work, we report
that ADhbi-pro-NGF stimulates processing of p75NTR
with - and -secretases, yielding a 20-kd intracellular
domain (p75ICD) that translocates to the nucleus. This
process was accompanied by delayed apoptosis. In AD,
p75ICD was significantly increased in human entorhinal
cortex. Although human frontal cortex has been de-
scribed as showing a higher pro-NGF increase in AD,
the increase in the entorhinal cortex paralleled p75NTR
processing in its intracellular domain. In addition, pro-
NGF isolated from AD-affected brains differed function-
ally from pro-NGF isolated from comparably aged con-
trol brains, with pro-NGF isolated from control brains
being unstable and undergoing degradation to NGF
when added to cell culture. As p75ICD and pro-NGF are
both mediators of apoptosis and are both found in in-
creased levels in the cerebral cortex in AD, the present
data have implications for understanding neuronal
degeneration in AD. (Am J Pathol 2006, 169:119–131; DOI:
10.2353/ajpath.2006.050787)
The highly multifunctional neurotrophin receptor p75NTR
(p75 neurotrophin receptor) belongs to the family of tu-
mor necrosis factor receptors,1 which share a repeated
cysteine domain in the extracellular domain. p75NTR
direct ligands have been referred to as the neurotrophins,
including neurotrophic growth factor (NGF), brain-de-
rived neurotrophic factor, neurothrophin 3, neurothrophin
4/5, and the pro-neurotrophins pro-brain-derived neuro-
trophic factor and pro-NGF. Of these, pro-NGF is the
most specific ligand and the one with the highest affinity.2
Rather than NGF, it has been shown to be the predomi-
nant form of this neurotrophin in the human brain.3
Recent studies have shown that in Alzheimer’s disease
(AD), brain levels of pro-NGF are increased in a stage-
dependent manner. It is expressed particularly in glial
cells as well as in cortical and hippocampal neurons.3–5
AD is characterized by the presence of senile plaques
composed of -amyloid (A) and neurofibrillary tangles
containing hyperphosphorylated tau, which are further
accompanied by degeneration of synapses and den-
drites and by cell death and loss of neurons.6
Several pieces of evidence support the idea that neu-
rotrophin binding to p75NTR can mediate cell death in
different neuronal models.7–9 Under NGF activation, the
ability of p75NTR to induce cell death depends on the
ratio of p75NTR/high affinity NGF receptor (TrkA) expres-
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sion.10 However, under pro-NGF activation, the receptor
complex composed of p75NTR and Sortilin mediates
apoptotic signals.11 Sortilin has been shown to be widely
expressed in rat cerebral neurons,12 although information
for other models is limited. The ratios of NGF:pro-NGF
and p75NTR:Sortilin:TrkA therefore emerge as critical
regulatory events in maintaining the balance between
survival and death for a given cellular model. Several
works support the idea that p75NTR is induced in a
number of pathological situations, such as multiple scle-
rosis, amyotrophic lateral sclerosis, osmotic stress, and
AD.13 For example, spinal cord injury induces an in-
crease in both p75NTR expression as well as NGF and
pro-NGF levels in some neuronal and glial cells.14,15
The finding that A directly binds p75NTR, inducing
apoptosis in several cell culture lines, is especially rele-
vant in neuronal apoptosis in AD.16–18 Furthermore,
p75NTR can be processed on both transmembrane do-
main sides by -secretase and -secretase consecu-
tively by a regulated intramembrane proteolysis. This has
been shown to be activated by phorbol esters (such as
phorbol 12-myristate 13-acetate)19,20 or by neurotrophin
binding to the receptor.21 -Secretase activity yields
p75NTR C-terminal fragments (CTF) of 25 to 30 kd
(p75CTF), containing the trans-membrane and intracellu-
lar domains, whereas -secretase activity yields p75NTR
intracellular domain (p75ICD), which has been described
as translocating to the nucleus in some cell models.21
Other similar processing by -secretase is known to oc-
cur in A precursor peptide, yielding A42 amylogenic
peptide.22 All these studies give -secretase a central
role in AD.
In the present work we report that in AD p75ICD is
significantly increased in human entorhinal cortex. We
also report that pro-NGF isolated from AD-affected brains
(ADhbi-pro-NGF) differs functionally from pro-NGF iso-
lated from comparably aged control brains (Chbi-pro-
NGF). ADhbi-pro-NGF stimulates processing of p75NTR
with - and -secretases yielding p75ICD, which translo-
cates to the nucleus. This process is needed for the
apoptosis caused by ADhbi-pro-NGF binding to p75NTR.
As both p75ICD and pro-NGF are increased in AD-af-
fected human brain cortex, the data we present here
could be relevant to the understanding of neuronal de-
generation in AD.
Materials and Methods
Cell Cultures and Treatments
Cells of the 3T3 cell line, stably transfected to express
human p75NTR (3T3-p75st; kindly provided by M.V.
Chao, Skirball, New York University, NY), were grown in
24-well plates at 15,000 cells/cm2 with Dulbecco’s mod-
ified Eagle’s medium (Gibco-BRL, Gaithersburg, MD)
supplemented with 10% fetal bovine serum (FBS). Before
treatment, cells were washed twice with serum-free me-
dium, and treatments were performed in 0.5% FBS me-
dium. Rat pheochromocytoma cell line (PC12 cells) was
grown in 24-well plates in Dulbecco’s modified Eagle’s
medium supplemented with 6% FBS, 6% horse serum, 2
mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid and antibiotics. Before treatment, cells were washed
twice with serum-free medium, and treatments were per-
formed in the absence of FBS medium. In all experi-
ments, controls were included with the elution buffer from
chromatography purification of hbi-pro-NGF. For -secre-
tase inhibition, pretreatment with 1 mol/L N-[N-(3,5-dif-
luorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester
(DAPT; Calbiochem, San Diego, CA) was performed.
Human Samples
Human cases are summarized in Table 1. Human brain
samples were provided by the Institute of Neuropathol-
ogy and Brain Bank of the Institut d’Investigacio´ Bio-
me`dica de Bellvitge-Hospital Universitari de Bellvitge
(Barcelona, Spain) following the approval of the corre-
sponding Ethics Committee. At autopsy, half of the brain
was fixed in 10% formalin for no less than 3 weeks,
whereas the other half was cut in coronal sections 1-cm
thick, frozen on dry ice, and stored at 80°C until use.
The neuropathological study was performed in formalin-
fixed, paraffin-embedded sections of the frontal, primary
motor, primary somatosensory, posterior parietal, primary
Table 1. Summary of Cases Examined in the Present Study
No.
Age
(years) Gender* Diagnostic
Braak stage,
according to A†
Braak stage,
according to tau pathology‡
Post mortem
delay (hours)
Used for Hbi-pro-NGF
purification§
1 82 F Nolesions A 0 11 
2 63 M Nolesions A 0 17
3 49 F Nolesions A 0 7 
4 80 F Nolesions A 0 21 
5 74 M Nolesions A 0 24 
6 86 F AD C V 10 
7 82 F AD C V 10 
8 69 M AD C V 6 
9 82 F AD C IV 5 
10 69 M AD C V 20
*F, female; M, male.
†A, B, and C, Braak and Braak’s classification of AD stages depending on amyloid plaques.
‡0–V, Braak and Braak’s classification of AD stages depending on the distribution and amount of neurofibrillary tangles.
§Samples labeled as  were used for independent hbi-pro-NGF purifications.
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and association visual, temporal superior, temporal infe-
rior, anterior insular, anterior cingulate, and entorhinal
cortices; subiculum and anterior and posterior levels of
the hippocampus; the caudate and putamen, nucleus
pallidus, amygdala, Meynert nucleus, and medial and
posterior levels of the thalamus; midbrain (two levels);
pons (two levels, including the locus ceruleus) and me-
dulla oblongata (two levels); and upper vermis, lateral
hemisphere, and dentate nucleus of the cerebellum. De-
waxed sections were stained with hematoxylin and eosin,
Luxol Fast Blue-Klu¨ver Barrera, or processed for immu-
nohistochemistry following the streptavidin-peroxidase
method (Supersensitive Kit, Menarini, Florence, Italy) or
with the EnVision System Peroxidase (diaminobenzidine)
procedure (Dako, Carpinteria, CA) for A (M. Sarasa,
Zaragoza, Spain, Boehringer-Mannheim, Mannheim,
Germany), tau (Sigma-Aldrich, St. Louis, MO), phospho-
tau (phospho-specific antibodies Thr-181, Ser-202, Ser-
214, Ser-262, Ser-396, and Ser-422; Calbiochem), B-
crystallin (Novocastra, New Castle Upon Tyne, UK),
-synuclein (Chemicon, Temecula, CA), ubiquitin (Dako),
phosphorylated neurofilament epitopes (Boehringer,
Ingelheim, Germany), and - and -tubulin (Sigma-
Aldrich). Neuropathological diagnosis and staging were
performed following Braak and Braak classification.23 A
summary of the cases examined in the present study is
shown in Table 1. Control and diseased cases were
processed in parallel. The frontal cortex (area 8), along
with the entorhinal cortex and anterior hippocampus,
were used for further immunohistochemical and bio-
chemical studies. Rabies virus infection was excluded by
immunohistochemistry using a mouse monoclonal anti-
rabies antibody (4G4; Abcam, Cambridge, UK).
Antibodies
Anti-human ICDp75 was either from Promega (G3231;
Madison, WI) or 9992 kindly provided by M.V. Chao.
Anti-p75NTR antibody (REX; directed against the ex-
tracellular domain) was kindly provided by L.F.
Reichardt (Howard Hughes Medical Institute, Univer-
sity of California). Anti--actin antibody (AC-15) was
obtained from Sigma-Aldrich. Anti-NRH2 antibody was
kindly provided by P.A. Barker (Montreal Neurological
Institute, McGill University, Canada). Secondary anti-
rabbit IgG-horseradish peroxidase was obtained from
Amersham. The following antibodies were used in the
neuropathological classification of the human brain
samples: A amyloid (M. Sarasa, Boehringer-Mann-
heim), tau (Sigma-Aldrich) phospho-tau (phospho-spe-
cific antibodies Thr-181, Ser-202, Ser-214, Ser-262,
Ser-396, and Ser-422; Calbiochem), B-crystallin (No-
vocastra), -synuclein (Chemicon), ubiquitin (Dako),
phosphorylated neurofilament epitopes (Boehringer),
and - and -tubulin (Sigma-Aldrich).
Immunocytochemistry and Confocal Imaging
The cells were grown and treated on precoated p-L-lysine
coverslips. After the indicated times of treatment, the
cells were fixed with 4% paraformaldehyde in phosphate-
buffered saline for 1 hour at room temperature and per-
meabilized with methanol for 10 minutes at room temper-
ature. The incubation with corresponding primary
antibody was done overnight at 4°C. Anti-human p75
(Promega) and anti-p75NTR (REX) antibody (kindly pro-
vided by L.F. Reichardt) were used to detect intra- and
extracellular domains of p75NTR, respectively. The sec-
ondary antibody incubation with anti-rabbit Alexa Fluor
488 (Promega) was for 1 hour at room temperature. After
washing with phosphate-buffered saline, the coverslips
were mounted with Mowiol, and fluorescence images
were acquired using a confocal microscopy setup
(Model IX81; Olympus, Tokyo, Japan, 60 PlanApo us-
ing Fluoview version 4.3) or an inverted epifluorescence
microscope (Olympus IX71, 20 LCPlanFl). To use an
objective criterion to determine whether a 3T3-p75st cell
was positive for ICD nuclear translocation, we performed
intensity profiles of confocal images. We selected cells as
positive if they show higher nuclear values than cellular
membrane values.
Western Blotting
Protein extracts from the frontal and entorhinal cortex
were prepared as described. Pieces weighing from 0.3 to
1.0 g were sonicated in 1% sodium dodecyl sulfate, 10
mmol/L Tris, pH 6.8 (Scharlab, Barcelona, Spain). Ho-
mogenates were centrifuged at 12,000  g for 10 min-
utes, and protein concentration in the supernatant was
determined by DC-Protein Assay (Bio-Rad, Hercules,
CA). 30 g of total protein was resolved in 12% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis,
transferred to Immobilon-P membranes (Millipore, Bil-
lerica, MA), and blocked for 1 hour at room temperature
in TBS-T (50 mmol/L Tris, pH 8.0, 133 mmol/L NaCl, 0.2%
Tween 20) with 5% skimmed milk. For immunodetection
of the p75NTR forms, membranes were incubated with
9992 anti-p75NTR antibody (1:2500 in TBS-T) or with
anti-p75NTR antibody (Promega, 1:1000 in TBS-T) at 4°C
overnight. After washing in TBS-T, membranes were in-
cubated with horseradish peroxidase-conjugated anti-
rabbit antibody (1:5000 in TBS-T) at room temperature for
1 hour. For detection, an ECL chemiluminescence sys-
tem (Amersham Biosciences, Piscataway, NJ) was used
in accordance with the manufacturer’s instructions. Mem-
branes were stripped and re-blotted with anti--actin an-
tibody (Sigma-Aldrich, 1:5000 in TBS-T) to assess correct
protein loading.
Isolation of Pro-NGF from Human Brain
The methodology was based on the protocol for isolation
of mature NGF from mouse submaxillar gland described
by Longo et al.24 Briefly, frozen human brain tissue from
AD-affected or control (see Table 1) frontal cortex (8 to
10 g) was homogenized in 20 ml of sterile water using a
Potter on ice. After centrifugation of homogenates
(2500  g for 1 hour at 4°C), supernatants were dialyzed
against 20 mmol/L Na2HPO4/NaH2PO4 (pH 6.8) overnight
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using a 10-kd molecular weight cut-off membrane
(Sigma-Aldrich). The samples were loaded on a DEAE-
Sepharose FF column (Amersham Biosciences) pre-
equilibrated in the same buffer. Eluted fractions having
absorbance A280  0.5 were equilibrated by a second
dialysis against 20 mmol/L Na2HPO4/NaH2PO4 (pH 6.8)
overnight. Salt concentration was adjusted to 0.4 mol/L
NaCl in 50 mmol/L CH3COONa (pH 4.0). The sample was
centrifuged at 2500  g for 30 minutes, and the super-
natant was loaded on a DEAE-Sepharose FF column
previously equilibrated with the same buffer. All of the
procedures were performed at 4°C. Eluted fractions with
absorbance A280  0.1 were collected, concentrated,
and analyzed by Western blot using antibodies against
either NGF (H20, Santa Cruz Biotechnology, Santa Cruz,
CA) or pro-NGF antibody.4 NGF protein was undetect-
able in all of the fractions obtained using H20 anti-NGF
antibody. Absence of -amyloid peptide or derived ag-
gregates in the eluted fractions was excluded by Western
blot using rabbit polyclonal anti-A1–40 and A1–42 anti-
bodies (Dr. M. Sarasa) or anti-A1 (Boehringer) used at a
dilution of 1:50.
Detection of Apoptosis in the Cultures
Cells were fixed with 4% paraformaldehyde. Nuclei were
stained with Hoechst 33258 (Sigma-Aldrich). The fluores-
cence was analyzed using an Olympus 20 LCPlan ob-
jective and documented with an Olympus DP70 camera.
The number of pyknotic nuclei was established, and the
percentage of apoptosis was determined. At least 500
nuclei in random, nonoverlapping fields per condition
were counted in each experiment. Apoptotic cells were
also detected by using terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling (TUNEL; in situ
cell death detection kit, POD; Roche Applied Science,
Mannheim, Germany), following the manufacturer’s
instructions.
Densitometry and Statistical Analysis
The density of the immunoreactive bands was deter-
mined by densitometry of the films using a Bio-Rad image
analysis system. Statistical significance between groups
was calculated using Student’s t-test.
Results
Increased Levels of p75ICD from p75NTR
Processing Observed in Vivo and in Vitro: AD
Cerebral Cortex and p75NTR-Expressing Cells
Stimulated with Pro-NGF or NGF
p75ICD 20-kd product from -secretase has recently
been suggested to be involved in p75NTR signal-
ing.21,25,26 -Secretase is active in AD-affected human
brain and has an important role in the etiopathogenesis of
this disease.27 The increase of p75NTR in AD-affected
human brain is not fully accepted in the literature. To
further investigate the pathophysiological role of p75, we
first wanted to verify a possible increase in the 20-kd
p75ICD levels in AD. We used an antibody raised against
the p75ICD as described in the Materials and Methods to
analyze samples from AD and control human frontal and
entorhinal cortex at an advanced stage of the disease
(stage C, following the staging of A amyloid burden of
Braak and Braak23) (Figure 1, A and B). The use of this
antibody showed the presence of 25- and 20-kd bands
corresponding to p75CTF and p75ICD as previously re-
ported,25 respectively, as sequential products of - and
-secretases. Both fragments appeared to increase in
AD entorhinal cortex (Figure 1A). Densitometry analysis
of the 20-kd band revealed significant differences be-
tween the control and AD brains in entorhinal cortex
(Figure 1B). However, no differences between control
and AD with respect to the amount of 75-kd p75NTR in
frontal and entorhinal cortex were observed.
In previous works, an increase in pro-NGF levels in
human AD cerebral cortex was reported.3–5 Here we
show a significant increase of both pro-NGF and p75NTR
processing to p75ICD in the same brain samples. The
pro-NGF increase in the entorhinal cortex in AD, as
shown in our previous publication,4 is lower than in frontal
cortex. Yet, p75NTR processing and pro-NGF levels in-
creased in parallel in the entorhinal cortex.
As it is has been noted that NGF is able to induce
-secretase-dependent p75ICD nuclear translocation,21
we wanted to assess if this effect could also be observed
following ADhbi-pro-NGF p75NTR stimulation. As can be
seen in Figure 2, ADhbi-pro-NGF was able to induce
higher p75ICD levels than NGF.
Pro-NGF Activation of p75NTR Induces Nuclear
Translocation of p75ICD but Not of the Full-
Length p75NTR
It has been reported that p75ICD translocates to the nu-
cleus on neurotrophin stimulation in RN22-SC cell line
and primary Schwann cells.21 Therefore, we wanted to
assess whether ADhbi-pro-NGF was responsible for
p75ICD yield and whether this was followed by nuclear
translocation. For this purpose, we first used a cell model
expressing high levels of p75NTR, such as 3T3-p75st,
which has a good dose response to this pro-neurotrophin
in terms of a high degree of apoptosis.4 Confocal images
of sequential sections of 3T3-p75st cells immunostained
with an antibody raised against p75ICD (see Materials
and Methods) showed increased perinuclear distribution
in ADhbi-pro-NGF-treated cells (Figure 3, A and B). Hoe-
scht staining of the same cells showed the localization of
the nuclei (Figure 4A). As shown in Figure 4B, the per-
centage of apoptosis in ADhbi-pro-NGF-treated cells was
low within the first 24 hours but increased significantly at
48 hours. This may explain the observation that positive
cells for p75ICD perinuclear translocation show non-
apoptotic nuclei. The criteria used to quantify percentage
of cells positive for perinuclear ICDp75 distribution are
detailed in the Materials and Methods. To distinguish
between the internalization of full-length p75NTR and the
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translocation of p75ICD, we used an antibody raised
against the extracellular domain of p75NTR (REX). As
shown in Figure 3C, immunoreactive signal remained
Figure 2. p75NTR shedding yielding ICD is induced by ADhbi-pro-NGF
and by NGF treatment. 3T3-p75st cells were serum-deprived (0.5% FBS)
and left untreated or treated, with increasing concentrations of ADhbi-
pro-NGF and NGF, for 12 hours. 30 g of total protein was used per lane.
A: Western blot using anti-p75ICD antibody (Promega) shows induction of
the 20-kd band. -Actin was used as a control of protein loading. B: The
experiment was repeated three times with similar results. Bands were
scanned, and 20-kd band density units are expressed as percentage of
75-kd corresponding units. Bars represent the mean  SD of three
independent experiments using Promega antibody (two experiments)
and 9992 antibody (one experiment).
Figure 1. p75ICD is increased in the frontal and entorhinal cortex in Alzhei-
mer’s disease. A: The p75ICD and p75CTF are detected as 20- and 25-kd
immunoreactive bands, respectively, with an antibody directed against the
intracellular domain of p75NTR (Promega). The content of p75ICD is clearly
increased in stage C (according to Braak and Braak, see Table 1 and Materials
and Methods) in AD entorhinal cortex (line AD) compared to controls (line
C). -Actin is a control of protein loading. B: Densitometric analysis of
anti-p75ICD immunodetected bands shows a significant increase of p75ICD
20-kd band in AD-affected entorhinal cortex. Bars represent the mean of five
samples of stage C (AD) and five samples of stage A (C). **P 0.01; Student’s
t-test.
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mainly in the cell membrane even in ADhbi-pro-NGF
treated cells.
Because the pattern of localization may depend on
many factors, such as the level of expression of p75NTR,
the presence or absence of other membrane proteins or
intracellular interacting proteins, we performed parallel
experiments with PC12 cells. This model expresses more
physiological levels of p75NTR than 3T3-p75st and un-
dergoes apoptosis following ADhbi-pro-NGF treatment.
Figure 5A shows that ADhbi-pro-NGF induced nuclear
translocation of a proportion of p75ICD present in the cell,
with immunofluorescence being more or less uniformly
distributed throughout the nucleus (Figure 5A, panel c). It
colocalized with Hoechst staining, even though there
were remaining traces of the signal in the cytoplasm. We
observed a lesser degree of nuclear p75ICD translocation
with NGF (Figure 5A, panel b) and in deprived cells
(Figure 5A, panel a). Following a similar approach, to
make sure that this nuclear localization did not corre-
spond to internalization of the full-length p75NTR, we also
used REX antibody (Figure 5B). Unprocessed p75NTR
remained mainly in the membrane in untreated and NGF-
treated cells (Figure 5B, panels a and b) and showed a
degree of internalization without nuclear translocation as
a consequence of the addition of ADhbi-pro-NGF (Figure
5B, panel c).
The time course of ICD nuclear translocation and
apoptosis of treated PC12 cells (Figure 5C) showed an
initial effect of ICD translocation (at 24 hours) and a
delayed increase in the number of apoptotic cells. At the
time chosen to best observe nuclear translocation (24
hours), the percentage of apoptotic cells was still very
low. Cells shown in the figures to be positive for translo-
cation were still not positive for apoptosis. To exclude the
possible cross-reaction between the anti ICDp75NTR anti-
bodies used and NRH2, we performed western blotting
with an anti-NRH2 antibody. As can be observed (Figure
5D), the 24-kd positive band in PC12 lysates was not
present in any of the control or AD-affected human brain
samples. Furthermore, ICD nuclear translocation is
clearly visible in an epifluorescence NRH2 immunostain-
ing image of PC12 cells treated with ADhbi-pro-NGF in
the same conditions as Figures 7 and 8. Further, the
patterns of NRH2 and ICD distribution were completely
different. NRH2 labeling was not visible in the nucleus.
Control Human Cerebral Cortex Contains a Pro-
NGF That Is Not Actively Involved in Inducing
Apoptosis or Nuclear p75ICD Translocation
A relevant question is whether there were any differences
in the potential pathogenicity of pro-NGF obtained from
AD when compared with pro-NGF obtained from age-
matched controls. Western blot in cerebral cortex lysates
showed a similar molecular weight pattern in AD and
controls, although the total amount of pro-NGF changed.4
However, it remains to be established whether ADhbi-
pro-NGF and Chbi-pro-NGF were equally efficient in in-
ducing apoptosis. Using the same purification procedure
(see Materials and Methods), we obtained pro-NGF from
both sources in similar yields. We performed four parallel
purifications from each source and assayed induction of
apoptosis in 3T3-p75st (Figure 6A) and in PC12 cells
Figure 3. ADhbi-pro-NGF induces internalization of p75ICD but not of the entire p75NTR in 3T3-p75st cells. 3T3-p75st cells were serum-deprived (0.5% FBS) and
left untreated (A) or treated with 25 ng/ml of ADhbi-pro-NGF (B and C) for 12 hours. Cells were washed, fixed, permeabilized, and immunostained using
anti-p75ICD (A and B) or REX antibodies (C). Representative confocal sequential optical sections of 10 m from the same cell are shown. Scale bars  40 m.
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(Figure 6B). As previously reported,4 the percentage of
apoptosis was higher in 3T3-75st cells than in PC12 cells.
Surprisingly, Chbi-pro-NGF was not able to induce apo-
ptosis in 3T3-p75st or PC12 cells, even at high concen-
trations. Because 50 ng/ml NGF is able to maintain sur-
vival and is very specific in inducing differentiation in
PC12 cells, we used this cell line to further study whether
protection from death following Chbi-pro-NGF treatment
(Figure 6B) was due to pro-NGF degradation to NGF.
Moreover, at the incubation time used for the treatment
(24 hours), even 100 ng/ml of mature NGF was not able to
induce a significant increase of apoptosis in PC12 cells.
Figure 6C shows that Chbi-pro-NGF, but not ADhbi-pro-
NGF, was able to differentiate PC12 cells to a degree
similar to that of NGF. This is an indication that Chbi-pro-
NGF is degraded in the cell culture to NGF. In contrast,
ADhbi-pro-NGF was especially stable under these
conditions.
To determine whether Chbi-pro-NGF had the capacity
to induce p75ICD nuclear translocation, PC12 cells were
deprived of or treated with Chbi-pro-NGF, ADhbi-pro-
NGF, or NGF. Nuclear or cytoplasmic localizations were
counted with the help of an inverted epifluorescence
microscope using anti-p75ICD antibody (Figure 7A). Ar-
rows in Figure 7A (panels a and d) represent the cyto-
plasmic distribution quantified in Figure 7B. Arrows in
Figure 7A (panels b and c) represent the nuclear distri-
bution quantified in Figure 7B. As can be observed in
Figure 7, Chbi-pro-NGF did not induce nuclear p75ICD
localization in PC12 cells treated with the same concen-
tration of ADhbi-pro-NGF (25 ng/ml). NGF was used at
the concentration shown to be effective for inducing sur-
vival and differentiation in this cell line (100 ng/ml). At this
concentration, NGF was more active than Chbi-pro-NGF
but less effective than ADhbi-pro-NGF. In sum, our re-
sults strongly suggest a role for ADhbi-pro-NGF in
neurodegeneration.
Inhibition of -Secretase Processing of p75NTR
Blocks Both p75ICD Nuclear Translocation and
Apoptosis Mediated by ADhbi-Pro-NGF
An increase in pro-NGF has been reported in AD.3,4
Because we have shown p75ICD to be present in the
same regions as pro-NGF, we were interested in study-
ing whether the nuclear translocation of p75ICD in-
duced by ADhbi-pro-NGF (Figure 8A) could be rele-
vant for the apoptosis caused by this pro-neurotrophin.
To assess whether -secretase processing of p75ICD
could be involved in the induction of apoptosis, we
used DAPT to specifically inhibit this enzyme. Nuclei
were stained with Hoechst, and the percentage of py-
knotic nuclei among the total number of nuclei was
measured as described in Materials and Methods (Fig-
ure 8B). TUNEL yielded similar results as those ob-
tained by morphological criteria (data not shown).
When stimulated with pro-NGF, PC12 cells showed
both apoptosis and p75ICD nuclear translocation. Pre-
treatment of these cells with DAPT completely blocked
p75ICD nuclear translocation, as well as apoptosis in-
duced by ADhbi-pro-NGF (Figure 8). The apoptosis
level under these conditions was even lower than with
serum deprivation, suggesting that p75NTR process-
ing could also be, at least partially, involved in PC12
apoptosis under conditions of deprivation (Figure 8B).
To confirm further that - and -secretase activities
were involved in p75NTR processing under ADhbi-pro-
NGF binding, we treated 3T3-p75st cells with ADhbi-
pro-NGF in both the presence and absence of DAPT
(Figure 9), under the same conditions shown to block
p75ICD nuclear translocation in PC12 cells (Figure 8).
As seen in Figure 9, the use of a -secretase inhibitor
completely blocked the yield of p75ICD, proportionally
increasing the amount of p75CTF. As previously de-
scribed in different cell models for p75NTR,25 and also
for different membrane-associated proteins such as A
precursor peptide and Notch,27 cleavage by -secre-
tase preceded -secretase activity. Here, we report
(Figure 9) that DAPT blocked the yield of p75ICD pro-
ducing an accumulation in p75CTF, which was also
sensitive to ADhbi-pro-NGF p75NTR activation; p75CTF
Figure 4. Induction of translocation of p75ICD after ADhbi-pro-NGF treat-
ment as a previous event to induction of apoptosis. A: 3T3-p75st cells were
serum-deprived (0.5% FBS), treated with 25 ng/ml ADhbi-pro-NGF for 24
hours, and immunostained for p75ICD. Scale bar  90 m. B: At time points
24 and 48 hours, the nuclear translocation (white bars) and the induction of
apoptosis (gray bars) were assayed. Percentages are corrected for serum-
deprived cells (0.5% FBS). Bars represent the mean  SD of three indepen-
dent experiments.
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levels were also increased following pro-neurotrophin
treatment.
Taken together these results suggest that pro-NGF
from AD brains, but not from controls, can induce
p75NTR processing by secretases, which are involved in
A precursor peptide and Notch processing. Structural
or modification differences between Chbi- and ADhbi-
pro-NGF and molecular mechanisms involved in p75ICD
apoptosis induction have yet to be elucidated.
Discussion
Our results indicate that p75ICD levels significantly in-
crease in AD in human entorhinal cortex in parallel with
pro-NGF levels. We have previously shown4 that pro-NGF
from AD-affected cortex can induce apoptotic death me-
diated by its interaction with p75NTR. In the present work,
our results suggest that pro-NGF treatment induces -
and -secretase processing of p75NTR, which yields a
p75ICD that is subsequently translocated to the nucleus.
This process is accompanied by a delayed induction of
apoptosis. More importantly, in this work we also demon-
strate that pro-NGF from human control cortex is unable
to induce p75NTR processing with p75ICD nuclear trans-
location or apoptosis.
ADhbi-Pro-NGF Stimulation of p75NTR Causes
p75ICD Nuclear Translocation and Apoptotic
Cell Death
p75NTR is known to be involved in signaling apoptosis in
a number of cell models of NGF binding.7–9 However,
marked variations have been reported, depending on the
plethora of intracellular adaptors and on the coreceptor
pattern in a given cellular context.13 In 2001, new insights
were provided when it was shown that pro-NGF binds
more strongly than NGF to p75NTR, inducing a higher
degree of apoptosis.2 Furthermore, the death induced by
ADhbi-pro-NGF through p75NTR is independent of the
presence of TrkA, because the pro-neurotrophin is not a
TrkA ligand. It has been reported that p75NTR is sub-
jected to shedding in a sequential process of regulated
intramembrane proteolysis. This process occurs by a
mechanism involving - and -secretase processing on
both sides near its trans-membrane domain, in a protein
kinase C-dependent manner.25The product of -secre-
tase is p75CTF, comprising the transmembrane domain
with an apparent molecular weight of 25 kd.25,26 The
product of -secretase processing is p75ICD with an ap-
parent molecular weight of 20 kd.25,26 It has been de-
scribed that -secretase activity is essential for the ac-
tivity of -secretase.25 p75ICD is difficult to be detected,
because it is described as being very unstable.19 The
proportion of p75ICD:p75CTF observed can present vari-
ations between models or may be the consequence of
different /-secretases activity and other processing
mechanisms. The data that we present here show that the
20-kd band is increased in AD-affected entorhinal cortex.
Only a faint 25-kd band can be observed, with relatively
constant levels. NRH2, a closely related homologue of
p75NTR, lacks the extracellular domain and does not
bind directly to NGF.28 Several studies support the idea
that NRH2 is not detected by the anti-p75ICD used in the
present study.21,28 We have used the anti-NRH2 antibody
to confirm that the p75ICD present in human cortex brain
samples, and increased in AD, is not NRH2. Only positive
controls of PC12 lysates, and not of human brain sam-
ples, showed a band of 24 kd corresponding to NRH2.
It has been shown recently that in a Schwannoma cell
line21 the yield of p75ICD and its nuclear localization are
dependent on neurotrophin binding to the receptor.
Other authors have shown no p75NTR processing20 or
only a weak p75ICD yield under NGF stimulation.25 In the
present work, we have shown that in deprived 3T3-p75st
cells both p75ICD and p75CTF are only barely detected.
Treatment with NGF or with ADhbi-pro-NGF showed that
a clear induction of p75ICD with a parallel p75ICD nuclear
translocation was stronger with ADhbi-pro-NGF.
Immunocytochemistry with an antibody raised against
the extracellular domain of p75NTR (REX) does not show
nuclear translocation under confocal microscopy, indi-
cating that p75ICD follows a different trafficking pathway
and localization than internalization of the whole p75NTR.
As described by Saxena et al,29 NGF activation of
p75NTR causes an internalization that is activated by
TrkA phosphorylation. This occurs through sequential in-
ternalization of both receptors in clathrin-coated vesicles
and early endosome vesicles, recycling of p75NTR, and
lysosomal degradation of TrkA. 3T3-p75st does not show
internalization of the whole receptor in NGF- or in pro-
NGF-stimulated cells. This can be explained by the lack
of TrkA expression in these cells. Comparing localization
of p75NTR using the REX antibody in pro-NGF-stimulated
3T3-p75st and PC12 cells, a degree of cytoplasmic in-
ternalization in PC12 not visible in 3T3-p75st can be
observed, where immunolabeling is restricted to the plas-
matic membrane. The fact that perinuclear or nuclear
localization in 3T3-p75st and PC12, respectively, stimu-
lated by pro-NGF, is only detected with anti-p75ICD and
not with REX reinforces the idea that nuclear or perinu-
clear translocation only occurs with p75ICD from p75NTR
processing by - and -secretases. Inhibitors of these
secretases completely abolished the process.
Until now, no information regarding p75NTR process-
ing or nuclear translocation of p75ICD in apoptosis was
Figure 5. ADhbi-pro-NGF induces nuclear translocation of p75ICD but not of the entire p75NTR in PC12 cells. PC12 cells were serum-deprived (a), serum-deprived
and treated with 100 ng/ml NGF (b), or serum-deprived and treated with 25 ng/ml ADhbi-pro-NGF (c). Cells were washed, fixed, permeabilized, immunostained
with anti-p75ICD antibody (A) or with REX antibody (B) and visualized with confocal microscopy. Nuclei were stained with Hoechst. C: Apoptosis (white bars)
and nuclear translocation of p75ICD (gray bars) were quantified at 24, 48, and 72 hours. Bars represent the mean  SD of three independent experiments. D:
Western blot using anti-NRH2 antibody shows a band in PC12 total cell lysate (lane 5), which is barely detectable in total lysates from human entorhinal cortex
(lanes 1 and 2) and frontal cortex (lanes 3 and 4). The arrow indicates apparent molecular weight of 24 kd. E: Epifluorescence NRH2 immunostaining image of
PC12 cells treated with 25 ng/ml ADhbi-pro-NGF for 24 hours shows the absence of NRH2 nuclear translocation. Scale bars  50 m.
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available. Recently, a first physiological role was noticed
for p75ICD yield under myelin-associated glycoprotein
activation in cerebellar neurons.26 In this model, - and
-secretase cleavage of p75NTR was necessary for ac-
tivation of Rho and inhibition of neurite outgrowth.
It is widely reported that p75NTR can interact with
different sets of receptors, depending on their respective
proportions and on the ligand availability. Sortilin recep-
tor has been described as being essential in p75NTR-
induced apoptosis activated by pro-NGF.11 The binding
of the pro-domain to Sortilin and of the mature NGF
domain to p75NTR starts a poorly understood cascade of
events leading to apoptosis. Future studies will be
needed to ascertain if shedding of p75NTR with the yield
and nuclear translocation of p75ICD is part of the process.
Initial interaction of receptors and ligands could recruit a
set of intracellular proteins that might orient the physio-
logical role of p75ICD in one direction or another.
Pro-NGF from AD-Affected Cortex Is Not Only
Present at Higher Levels but Is Also More Active
in Inducing Apoptosis through p75NTR
Processing
As previously reported, pro-NGF is increased in human
cortex brain in a manner that is dependent on the
progress of the disease, reaching maximum levels in
advanced stages.4 We have also shown that pro-NGF
isolated from AD cerebral cortex (ADhbi-pro-NGF) can
induce apoptosis in neuronal cell cultures through its
interaction with the p75NTR receptor in a mechanism that
is dependent on -secretase shedding of the receptor.
As control brains also present some basal levels of pro-
NGF,4 it was interesting to explore whether there were
any differences in the process of apoptosis induction by
pro-NGF between AD-affected brains and controls. We
first wanted to assess whether pro-NGF isolated from the
two kinds of sources gave rise to similar physiological
effects, or whether the only difference was due to the
increased amount of the pro-neurotrophin in AD. Surpris-
ingly, pro-NGF isolated from four different control sam-
ples was not able to induce apoptosis in any of the cell
models used. Previous studies performed with the bac-
terially expressed wild-type pro-NGF showed the func-
tionality of the protein by partially hydrolyzing the pro-
domain with trypsin, demonstrating that the NGF resulting
from the subsequent hydrolysis could induce the survival
of dorsal root ganglia neurons at a similar rate as seen
with the same concentration of NGF.30 NGF is the only
neurotrophin reported as inducing neuronal differentia-
tion in PC12 cells through its interaction with TrkA. This
Figure 6. ADhbi-pro-NGF but not Chbi-pro-NGF induces apoptosis in
p75NTR-expressing cells. Cultured 3T3-p75st cells (A) and PC12 cells (B and
C) were serum-deprived (0.5% FBS) and left untreated or treated for 24 hours
with increasing concentrations of either ADhbi-pro-NGF (}) or Chbi-pro-
NGF (▫) or with NGF (100 ng/ml) (‚). Apoptosis was evidenced by nuclear
morphology after Hoechst staining. Apoptosis increases in a dose-dependent
manner with ADhbi-pro-NGF (A and B). In contrast, Chbi-pro-NGF treatment
resulted in cell differentiation. Differentiated PC12 cells are those with neurite
extensions longer than the cell body (C). Values represent the mean  SD of
three independent experiments.
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interaction also activates strong survival signals that are
able to block apoptosis acting on a number of molecular
targets. This would make it difficult to detect apoptosis
caused by stimulation of p75NTR under conditions of
phosphatidylinositol 3-kinase/protein kinase A activation.
The study of interactions between these two pathways,
pro-NGF/p75NTR and phosphatidylinositol 3-kinase/pro-
tein kinase A, is the aim of future work.
As we previously reported,4 ADhbi-pro-NGF could not
sustain the survival and/or the differentiation of PC12
cells. However, when ADhbi-pro-NGF was partially di-
gested by trypsin, PC12 survival and differentiation were
observed. Moreover, partially digested ADhbi-pro-NGF
protected PC12 cells from death caused by deprivation,
to the same extent as NGF, thus indicating that NGF is
obtained as a product of trypsin digestion. Based on
these findings, we wanted to assess whether Chbi-pro-
NGF was either inducing apoptosis, as does ADhbi-pro-
NGF, or survival and differentiation, as does NGF. The
assay on PC12 cells shows that Chbi-pro-NGF was de-
graded to NGF when it was added to the culture, induc-
ing neuritogenesis. As we described previously, the
53-kd pro-NGF isoform is at least partially deglycosylated
by N-glycanase treatment.4 In that work, we did not ex-
clude the possibility that the other isoforms as well as the
53-kd isoform were modified by different glycosylations
or by other post-translational modifications such as gly-
cation. Moreover, we cannot exclude the possibility that
differences in glycosylation or any other kind of modifi-
cations between control and AD brain samples may not
be distinguished by Western blot and that these modifi-
cations might account for the differences in stability or in
protease degradation. Glycosylation and glycation are
common modifications of proteins in AD. Among other
proteins, glycosylation of acetylcholinesterase has been
used as a marker for the disease.31 Further work needs to
be done to test the hypothesis that post-translational
modifications occurring in AD could be responsible for
protecting ADhbi-pro-NGF from its processing, thus
Figure 7. A: ADhbi-pro-NGF but not Chbi-pro-NGF induces nuclear trans-
location of p75ICD in PC12 cells. PC12 cells were serum-deprived and left
untreated (a) or treated for 24 hours with 100 ng/ml of NGF (b), 25 ng/ml
ADhbi-pro-NGF (c), or 25 ng/ml Chbi-pro-NGF (d). Cells were washed,
fixed, permeabilized, and immunostained with anti-p75ICD antibody. Ar-
rows in a and d are representative of the cytoplasmic distribution quanti-
fied in B. Arrows in b and c are representative of the nuclear distribution
quantified in B. Cytoplasmic and nuclear p75ICD was examined with the
help of an inverted epifluorescence microscope. Bars represent the mean of
percentages of at least 500 cells per condition (B). *P  0.05; **P  0.01;
Student’s t-test. Values result from three independent experiments. Scale
bar  80 m.
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switching its function from insuring survival and differen-
tiation to causing neuronal.
Taken together, the present results indicate that a
cascade of events relevant to the etiopathogenesis of
AD could begin with an increase of pro-NGF. The
activation of p75NTR by the pro-neurotrophin would
lead to the processing of the receptor by - and
-secretases. We found that this processing can be
increased in AD to yield p75ICD, which tends to trans-
locate to the nucleus. The relationship between this
process and the induction of neuronal apoptosis is still
not fully understood.
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